MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaci.2024.10.031

Медицинская библиотека · The Journal of allergy and clinical immunology · 2024

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.

Weidinger Stephan, Blauvelt Andrew, Papp Kim A, Reich Adam, Lee Chih-Hung, Worm Margitta, Lynde Charles, Kataoka Yoko, Foley Peter, Wei Xiaodan, Wong Wanling, Solente Anne-Catherine, Weber Christine, Adelman Samuel, Davey Sonya, Hurbin Fabrice, Rynkiewicz Natalie, Yen Karl, O'Malley John T, Bernigaud Charlotte

СтатьяРандомизированное исследованиеКлиническое исследование II фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Amlitelimab, a fully human nondepleting mAb targeting OX40 ligand on antigen-presenting cells, could prevent T-cell-driven inflammation seen in atopic dermatitis (AD).

OBJECTIVE

This trial evaluated the efficacy and safety of amlitelimab in adults with AD.

METHODS

In this 2-part, phase 2b, randomized, double-blinded placebo-controlled trial (ClinicalTrials.gov identifier NCT05131477), patients received subcutaneous amlitelimab every 4 weeks at doses of 250 mg plus a 500-mg loading dose, 250 mg, 125 mg, or 62.5 mg or placebo for 24 weeks in Part 1 (1:1:1:1:1 randomization). In Part 2, clinical responders were reallocated 3:1 to stop taking amlitelimab or continue the previous dose regimen for 28 weeks. The primary end point was percentage of change in Eczema Area and Severity Index (EASI) from baseline to week 16.

RESULTS

In all, 390 and 190 patients enrolled in Part 1 and Part 2, respectively. A significant percentage of change decrease in EASI was observed with amlitelimab doses versus with placebo (P < .001). Clinical responses at week 24 (Investigator Global Assessment 0/1 and/or a 75% reduction in EASI) were maintained at week 52 in patients continuing or stopping amlitelimab. Of the patients maintaining clinical response at week 52 after no longer receiving treatment, more than 80% had serum amlitelimab concentrations less than the 4-μg/mL threshold for several weeks before week 52. Reductions in AD-related biomarkers during Part 1 were maintained through Part 2. Amlitelimab was well tolerated over 52 weeks.

CONCLUSIONS

Amlitelimab treatment significantly reduced clinical and biomarker responses, and was well tolerated in adults with AD through week 52. Sustained responses were observed in the majority of patients for 28 weeks after they had stopped taking amlitelimab.

Для цитирования: Weidinger Stephan, Blauvelt Andrew, Papp Kim A, Reich Adam, Lee Chih-Hung, Worm Margitta, Lynde Charles, Kataoka Yoko, Foley Peter, Wei Xiaodan, Wong Wanling, Solente Anne-Catherine, Weber Christine, Adelman Samuel, Davey Sonya, Hurbin Fabrice, Rynkiewicz Natalie, Yen Karl, O'Malley John T, Bernigaud Charlotte. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.. The Journal of allergy and clinical immunology. 2024. DOI: 10.1016/j.jaci.2024.10.031.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.